In one study assessing loss to follow-up in patients receiving anti-VEGF injections or PRP for proliferative diabetic retinopathy, younger age, non-White race, and lower regional average adjusted gross incomes were identified as risk factors for loss to follow-up [14]. Here, VEGFA is linked to proliferative diabetic retinopathy.